Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Liabilities and Shareholders Equity (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Liabilities and Shareholders Equity for 5 consecutive years, with $76.6 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 47.02% to $76.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $408.8 million through Dec 2025, down 40.57% year-over-year, with the annual reading at $76.6 million for FY2025, 47.02% down from the prior year.
  • Liabilities and Shareholders Equity hit $76.6 million in Q4 2025 for Kezar Life Sciences, down from $97.7 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $317.5 million in Q2 2022 to a low of $76.6 million in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $196.5 million across 5 years, with a median of $189.5 million in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: soared 132.85% in 2022 and later plummeted 47.02% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $217.9 million in 2021, then soared by 37.46% to $299.6 million in 2022, then dropped by 26.15% to $221.2 million in 2023, then plummeted by 34.6% to $144.7 million in 2024, then tumbled by 47.02% to $76.6 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for KZR at $76.6 million in Q4 2025, $97.7 million in Q3 2025, and $109.1 million in Q2 2025.